The mid-to-long-term vision that the company drew up in 2007, set the targets: ‘Establish a solid foundation for the domestic business’, ‘Expand the international business operation’ and ‘Enrich the R&D product pipeline to realize the future vision’, in envisioning its corporate status for the next ten years.
For its vision of the next 15 years, the company aims to become an internationally competitive R&D-oriented pharmaceutical firm and to have two solid mainstreams of revenue, from domestic operations and from international operations.
In the three-year first MTBP ending with fiscal 2009, the company worked to upgrade and strengthen its business platform for globalization and submitted a New Drug Application (NDA) to the FDA ahead of schedule for lurasidone, an investigational agent for schizophrenia being developed globally. In addition, the company progressed in its globalization by establishing and expanding its business platform and R&D facilities in North America, through the acquisition of Sepracor.
The first MTBP was for three years, but taking into consideration the status of Sepracor and the global strategic product lurasidone, which the company believes will have a substantial impact on performance, it set a five-year term for the second MTBP. During the second phase, the company will strive to achieve the vision, and proceed to a new stage by raising its creative capabilities and further transforming itself.
The company expects net sales of JPY440bn in the year 2014, with pharmaceuticals segment to earn JPY375bn. The operating income is expected to be JPY70bn, with EBITDA of JPY90bn.